Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Brodsky

Orthopaedic Surgery Dallas, TX Medical Doctor

NPI 1740270206 CMS profile 169586

3900 Junius St, Suite 500, Dallas, TX 75246

Open in the dashboard

General payments

$2,531,170

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Brodsky of Dallas, TX is reported in the CMS Open Payments database as having received $2,531,170 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $458,438 8
2024 General $406,740 10
2023 General $447,242 8
2022 General $380,934 11
2021 General $306,197 10
2020 General $273,233 23
2019 General $258,387 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Brodsky
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to James Brodsky were reported at $458,438. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year James Brodsky Orthopaedic Surgery median Middle half National median
2019 $258,387 $644 $140–$2,844 $163
2020 $273,233 $312 $75–$1,860 $114
2021 $306,197 $520 $117–$2,495 $132
2022 $380,934 $598 $128–$2,731 $149
2023 $447,242 $461 $128–$2,264 $160
2024 $406,740 $497 $134–$2,475 $164
2025 $458,438 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,913,885 36 payments
  2. Integra LifeSciences Corporation $584,504 44 payments
  3. Stryker Corporation $31,248 9 payments
  4. Ascension Orthopedics, Inc. $1,250 1 payment
  5. restor3d, inc. $207 1 payment
  6. Zimmer Biomet Holdings, Inc. $22 1 payment
  7. Wright Medical Technology, Inc. $20 1 payment
  8. Dynasplint Systems Inc. $18 1 payment
  9. DePuy Synthes Sales Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $2,444,833 49 payments
  2. Consulting Fee $71,910 24 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,383 3 payments
  4. Travel and Lodging $1,175 4 payments
  5. Food and Beverage $868 15 payments
Products named General payments · program years 2019–2025
  1. Panta 2 $1,911,499 31 payments
  2. PANTA NAIL $500,831 43 payments
  3. PANTA 2 ARTHRODESIS NAIL SYSTEM $84,923 2 payments
  4. SALTO TALARIS TOTAL ANKLE PROSTHESIS $50,879 29 payments
  5. CADENCE ANKLE REPLACEMENT SYSTEM $50,879 29 payments
  6. TOTAL FOOT SYSTEM $50,879 29 payments
  7. STAR $30,750 3 payments
  8. ASNIS $15,000 1 payment
  9. VARIAX $15,000 1 payment
  10. ANCHORAGE $15,000 1 payment
  11. Other $34,357 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

129

Median for Orthopedic Surgery: 203

Drug cost

$1,924

Median for Orthopedic Surgery: $1,433

Branded share of claims

42.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 17 $909
Gabapentin Generic 18 $316
Ondansetron Odt Ondansetron Brand 30 $270
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 25 $241
Oxycodone Hcl Generic 22 $126
Meloxicam Generic 17 $61

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$77,511

Medicare's payments for the services billed

Medicare patients

269

Average age 73

Services billed

1,297

181 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 65%
Depression 25%
Ischemic heart disease 22%
Osteoporosis 21%
Diabetes 19%
Chronic kidney disease 18%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record